

File reference	W17FOI289
Key words	Intra-vitreous vials/implants
Date of release	05/07/2017
Attachments	Yes L3

Freedom of Information Act Disclosure log - Reply Extract

You asked

Within your trust, how many intra-vitreous vials/implants have been used in the latest 4 months, if possible between January and April 2017?

Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

Our response

Please find the figures below for the time period 1/1/17 to 30/4/17 as requested.

We have excluded vials of Avastin which are booked out to cancer services. The figure below specifically refers to ophthalmology use.

	Lucentis (ranibizumab) Injections	Avastin (bevacizumab) Injections	Eylea (aflibercept) Injections	Illuvien (Fluocinolone) Implants	Ozudex (Dexametha sone) Implants
Total Vials / Implants	1370	17	890	Five or fewer	155
Vials / Implants for Wet Age Related Macular Degeneration (wAMD)					

Legal notes

Plymouth Hospitals NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles. This is in accordance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i), the personal information exemption as described in the Freedom of Information Act. A detailed rationale is provided in the attached document L3.

Attachments included: Yes –L3